Goldman Sachs’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Goldman Sachs’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-232,325	Closed	-$2.3M	–	6741
2022 Q2	$2.3M	Sell	232,325 -900	-0.4%	-$8.82K	﹤0.01%	3922
2022 Q1	$2.3M	Hold	233,225	–	–	﹤0.01%	4135
2021 Q4	$2.29M	Sell	233,225 -1,194	-0.5%	-$11.7K	﹤0.01%	4140
2021 Q3	$2.28M	Sell	234,419 -600	-0.3%	-$5.82K	﹤0.01%	4066
2021 Q2	$2.27M	Buy	235,019 +174,915	+291%	+$1.7M	﹤0.01%	4090
2021 Q1	$584K	Buy	+60,104	New	+$582K	﹤0.01%	5004

Other funds holding BIOT

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CCP

Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return

RiverPark Advisors New York $219M AUM 14.91% 1-Year Est. Return

Cohanzick Management Pleasantville, New York $231K AUM 3.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs's BIOT Position: Q3 2022 in Review

Goldman Sachs sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q3 2022, closing a stake of 232,325 shares — an estimated $2.3M sold.

Goldman Sachs first reported a position in BIOT in Q1 2021 and held it in 6 quarters. The position peaked at $2.3M in Q2 2022. 69 funds tracked by Wall St. Rank hold BIOT as of Q3 2022.

Goldman Sachs reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Goldman Sachs sold 232,325 Biotech Acquisition Company Class A Ordinary Shares shares in Q3 2022, an estimated $2.3M.
Goldman Sachs first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2021 and held it in 6 quarters.
Goldman Sachs's Biotech Acquisition Company Class A Ordinary Shares position peaked at $2.3M in Q2 2022.
69 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q3 2022.

Based on Goldman Sachs's 13F filing for Q3 2022, filed 14 Nov 2022.